Dihydroergocristine API Manufacturers

General Description:

Dihydroergocristine, identified by CAS number 17479-19-5, is a notable compound with significant therapeutic applications. Dihydroergocristine is part of the ergoloid mixture products. It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline. To know more about ergoloid mixtures, please visit .

Indications:

This drug is primarily indicated for: Dihydroergocristine is used in some countries such as Brasil as a single agent for the treatment of cerebral and peripheric vascular events. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit . Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Metabolism:

Dihydroergocristine undergoes metabolic processing primarily in: The major metabolite of dihydroergocristine is 8'-hydroxy-dihydroergocristine is produced in the liver. The modification of dihydroergocristine in the body is very extensive and it has been observed as an almost complete absence of the unchanged drug. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit . This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.

Absorption:

The absorption characteristics of Dihydroergocristine are crucial for its therapeutic efficacy: Dihydroergocristine presents an absorption in the digestive tract of about 25% of the administered dose. When dihydroergocristine was orally administered in humans and the peak plasma concentration of 0.28 mcg/l was achieved after 0.46 hours. In the same report, the AUC was reported to be 0.39 mcg/l.h. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit . The drug's ability to rapidly penetrate into cells ensures quick onset of action.

Half-life:

The half-life of Dihydroergocristine is an important consideration for its dosing schedule: The half-life of dihydroergocristine has only been studied as part of the therapeutic mixture, please refer to . This determines the duration of action and helps in formulating effective dosing regimens.

Protein Binding:

Dihydroergocristine exhibits a strong affinity for binding with plasma proteins: Dihydroergocristine can be found in a bound state to plasma proteins in a proportion of even 68% of the administered dose. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit . This property plays a key role in the drug's pharmacokinetics and distribution within the body.

Route of Elimination:

The elimination of Dihydroergocristine from the body primarily occurs through: The most important elimination route of dihydroergocristine is in via the bile and it accounts for over 85% of the eliminated dose. Urine elimination accounts only for 5% of the administered dose. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit . Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.

Volume of Distribution:

Dihydroergocristine is distributed throughout the body with a volume of distribution of: Dihydroergocristine presents a large volume of distribution of 52 l/kg. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit . This metric indicates how extensively the drug permeates into body tissues.

Clearance:

The clearance rate of Dihydroergocristine is a critical factor in determining its safe and effective dosage: Dihydroergocristine presents a high systemic clearance rate of 2.65 l/h.hg. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit . It reflects the efficiency with which the drug is removed from the systemic circulation.

Pharmacodynamics:

Dihydroergocristine exerts its therapeutic effects through: Dihydroergocristine has been shown to present effect on memory and cognition. This activity in the brain is been reported by an increase in glutathione in age-related brain states. The reported effect on serotonin and adrenergic receptors has also been correlated to an inhibition of platelet aggregation. It has also been reported that individuals exposed to dihydroergocristine may present an amphoteric vasoregulating activity either hypotensive in hypertensive individuals or hypertensive in hypotensive individuals. This action is performed by promoting a dilating action in the contracted arteries and a tonic action in the dilated arteries and arterioles. The vasoregulating effect causes an increase in cerebral blood flow and oxygen consumption by the brain, which correlates with the brain protective function of dihydroergocristine. In Alzheimer studies, dihydroergocristine reduced the amyloid-beta levels in different cell types. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit . The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Dihydroergocristine functions by: Dihydroergocristine mechanism of action seems to be related to a noncompetitive antagonistic activity in the serotonin receptors as well as a double partial agonist/antagonist activity in dopaminergic and adrenergic receptors. In Alzheimer studies, dihydroergocristine act as a direct inhibitor of γ-secretase. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Toxicity:

Classification:

Dihydroergocristine belongs to the class of organic compounds known as lysergamides. These are amides of Lysergic acids, classified under the direct parent group Lysergamides. This compound is a part of the Organic compounds, falling under the Alkaloids and derivatives superclass, and categorized within the Ergoline and derivatives class, specifically within the Lysergic acids and derivatives subclass.

Categories:

Dihydroergocristine is categorized under the following therapeutic classes: Adrenergic Agents, Adrenergic Antagonists, Agents that produce hypertension, Alkaloids, BSEP/ABCB11 Substrates, Cardiovascular Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Substrates, Ergot Alkaloids and Derivatives, Ergotamines, Heterocyclic Compounds, Fused-Ring, Neurotransmitter Agents, Peripheral Vasodilators, Vasodilating Agents. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Experimental Properties:

Further physical and chemical characteristics of Dihydroergocristine include:

• Water Solubility: 10 mg/ml
• Melting Point: 213-215 ºC
• Boiling Point: 899.3 ºC at 760 mm Hg
• logP: 5.86
• pKa: 6.9